Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®)

被引：0
|
作者：
Marye J. Boers-Sonderen
Carla M. L. van Herpen
Winette T. A. van der Graaf
Ingrid M. E. Desar
Mirjam G. W. Arens- van der Logt
Yvo M. de Beer
Petronella B. Ottevanger
Nielka P. van Erp
机构：
[1] Radboud University Medical Centre,Department of Medical Oncology, 452
[2] Maastricht University Medical Centre+,Department of Clinical Pharmacy and Toxicology
[3] Maastricht University,School CAPHRI
[4] Maastricht University,Department of Toxicology
[5] Radboud University Medical Centre,Department of Clinical Pharmacy
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Pegylated liposomal doxorubicin; Pharmacokinetics; Pharmacodynamics; Progression-free survival; Toxicities;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：457 / 463
页数：6
相关论文
共 50 条
  • [21] Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
    Anders, Carey K.
    Adamo, Barbara
    Karginova, Olga
    Deal, Allison M.
    Rawal, Sumit
    Darr, David
    Schorzman, Allison
    Santos, Charlene
    Bash, Ryan
    Kafri, Tal
    Carey, Lisa
    Miller, C. Ryan
    Perou, Charles M.
    Sharpless, Norman
    Zamboni, William C.
    PLOS ONE, 2013, 8 (05):
  • [22] Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains
    Song, Gina
    Suzuki, Oscar T.
    Santos, Charlene M.
    Lucas, Andrew T.
    Wiltshire, Tim
    Zamboni, William C.
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2016, 12 (07) : 2007 - 2017
  • [23] Pegylated liposomal doxorubicin: Tolerability and toxicity
    Goram, AL
    Richmond, PL
    PHARMACOTHERAPY, 2001, 21 (06): : 751 - 763
  • [24] Parmacokinetics (PK) of oral vinorelbine (VNR) in association with pegylated liposomal doxorubicin (PLD) in metastatic ovarian carcinoma
    Airoldi, M.
    Cattel, L.
    Milla, P.
    Passera, R.
    Pedani, F.
    Crova, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Combined regimen of temozolomide and liposomal pegylated doxorubicin in glioblastoma - Toxicity and efficacy
    Hau, P
    Jauch, T
    Steinbrecher, A
    Bogdahn, U
    NEUROLOGY, 2006, 66 (05) : A336 - A336
  • [26] Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx®) as Pressurized Intraperitoneal Aerosol Chemotherapy
    Robella, Manuela
    Vaira, Marco
    Argenziano, Monica
    Spagnolo, Rita
    Cavalli, Roberta
    Borsano, Alice
    Gentilli, Sergio
    De Simone, Michele
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [27] Intrahepatic pegylated liposomal doxorubicin (PLD) in patients with liver malignancies
    Granetto, C.
    Fea, E.
    Colantonio, I
    Di Costanzo, G.
    Garrone, O.
    Gasco, M.
    Occelli, M.
    Heouaine, A.
    Numico, G.
    Merlano, M.
    ANNALS OF ONCOLOGY, 2006, 17 : 32 - 32
  • [28] Pegylated Liposomal Doxorubicin (PLD) in the treatment of advanced Cutaneous Lymphomas
    Cantonetti, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 : S14 - S14
  • [29] Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer
    Lorusso, D
    Ferrandina, G
    Lo Voi, R
    Fagotti, A
    Scambia, G
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 98 - 103
  • [30] Evaluation of the recurrence therapy of the ovarial carcinoma by means of pegylated liposomal doxorubicin (Caelyx®)
    Steppan, I
    Sevelda, U.
    Reimer, D.
    Marth, C.
    Zeimet, A. G.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 (04) : 435 - 435
12345